SYNAPTICS Inc — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that SYNAPTICS Inc filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2013 | Jun 29, 2013 | $663.59M | Aug 19, 2013 |
| FY2013 | Jun 30, 2012 | $548.23M | Aug 19, 2013 |
| FY2013 | Jun 25, 2011 | $598.54M | Aug 19, 2013 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 28, 2025 | $1.07B | Aug 21, 2025 |
| FY2025 | Jun 29, 2024 | $959.40M | Aug 21, 2025 |
| FY2025 | Jun 24, 2023 | $1.36B | Aug 21, 2025 |
| FY2024 | Jun 25, 2022 | $1.74B | Aug 23, 2024 |
| FY2023 | Jun 26, 2021 | $1.34B | Aug 18, 2023 |
| FY2022 | Jun 27, 2020 | $1.33B | Aug 22, 2022 |
| FY2021 | Jun 29, 2019 | $1.47B | Aug 23, 2021 |
| FY2020 | Jun 30, 2018 | $1.63B | Aug 21, 2020 |
| FY2019 | Jun 24, 2017 | $1.72B | Aug 23, 2019 |
| FY2018 | Jun 25, 2016 | $1.67B | Aug 24, 2018 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Jun 24, 2017 | $1.72B | Aug 18, 2017 |
| FY2017 | Jun 25, 2016 | $1.67B | Aug 18, 2017 |
| FY2017 | Jun 27, 2015 | $1.70B | Aug 18, 2017 |
| FY2016 | Jun 28, 2014 | $947.50M | Aug 26, 2016 |
| FY2015 | Jun 29, 2013 | $663.60M | Aug 25, 2015 |
| FY2014 | Jun 30, 2012 | $548.23M | Aug 22, 2014 |
| FY2013 | Jun 25, 2011 | $598.54M | Aug 19, 2013 |
| FY2012 | Jun 26, 2010 | $514.89M | Sep 21, 2012 |
| FY2011 | Jun 27, 2009 | $473.30M | Aug 22, 2011 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 28, 2025 | $480.40M | Aug 21, 2025 |
| FY2025 | Jun 29, 2024 | $439.80M | Aug 21, 2025 |
| FY2025 | Jun 24, 2023 | $715.90M | Aug 21, 2025 |
| FY2024 | Jun 25, 2022 | $943.10M | Aug 23, 2024 |
| FY2023 | Jun 26, 2021 | $611.20M | Aug 18, 2023 |
| FY2022 | Jun 27, 2020 | $543.10M | Aug 22, 2022 |
| FY2021 | Jun 29, 2019 | $497.10M | Aug 23, 2021 |
| FY2020 | Jun 30, 2018 | $480.10M | Aug 21, 2020 |
| FY2019 | Jun 24, 2017 | $523.60M | Aug 23, 2019 |
| FY2018 | Jun 25, 2016 | $581.50M | Aug 24, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 28, 2025 | ($47.80M) | Aug 21, 2025 |
| FY2025 | Jun 29, 2024 | $125.60M | Aug 21, 2025 |
| FY2025 | Jun 24, 2023 | $73.60M | Aug 21, 2025 |
| FY2024 | Jun 25, 2022 | $257.50M | Aug 23, 2024 |
| FY2023 | Jun 26, 2021 | $79.60M | Aug 18, 2023 |
| FY2022 | Jun 27, 2020 | $118.80M | Aug 22, 2022 |
| FY2021 | Jun 29, 2019 | ($22.90M) | Aug 23, 2021 |
| FY2020 | Jun 30, 2018 | ($124.10M) | Aug 21, 2020 |
| FY2019 | Jun 24, 2017 | $48.80M | Aug 23, 2019 |
| FY2018 | Jun 25, 2016 | $72.20M | Aug 24, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 28, 2025 | ($94.10M) | Aug 21, 2025 |
| FY2025 | Jun 29, 2024 | ($101.60M) | Aug 21, 2025 |
| FY2025 | Jun 24, 2023 | $154.30M | Aug 21, 2025 |
| FY2024 | Jun 25, 2022 | $350.40M | Aug 23, 2024 |
| FY2023 | Jun 26, 2021 | $147.00M | Aug 18, 2023 |
| FY2022 | Jun 27, 2020 | $68.90M | Aug 22, 2022 |
| FY2021 | Jun 29, 2019 | ($6.30M) | Aug 23, 2021 |
| FY2020 | Jun 30, 2018 | ($61.90M) | Aug 21, 2020 |
| FY2019 | Jun 24, 2017 | $64.70M | Aug 23, 2019 |
| FY2018 | Jun 25, 2016 | $75.20M | Aug 24, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 28, 2025 | $346.80M | Aug 21, 2025 |
| FY2025 | Jun 29, 2024 | $336.30M | Aug 21, 2025 |
| FY2025 | Jun 24, 2023 | $351.20M | Aug 21, 2025 |
| FY2024 | Jun 25, 2022 | $367.30M | Aug 23, 2024 |
| FY2023 | Jun 26, 2021 | $313.40M | Aug 18, 2023 |
| FY2022 | Jun 27, 2020 | $302.50M | Aug 22, 2022 |
| FY2021 | Jun 29, 2019 | $342.70M | Aug 23, 2021 |
| FY2020 | Jun 30, 2018 | $363.20M | Aug 21, 2020 |
| FY2019 | Jun 24, 2017 | $292.30M | Aug 23, 2019 |
| FY2018 | Jun 25, 2016 | $311.20M | Aug 24, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 28, 2025 | $180.30M | Aug 21, 2025 |
| FY2025 | Jun 29, 2024 | $161.30M | Aug 21, 2025 |
| FY2025 | Jun 24, 2023 | $175.00M | Aug 21, 2025 |
| FY2024 | Jun 25, 2022 | $168.40M | Aug 23, 2024 |
| FY2023 | Jun 26, 2021 | $144.90M | Aug 18, 2023 |
| FY2022 | Jun 27, 2020 | $127.00M | Aug 22, 2022 |
| FY2021 | Jun 29, 2019 | $131.30M | Aug 23, 2021 |
| FY2020 | Jun 30, 2018 | $154.00M | Aug 21, 2020 |
| FY2019 | Jun 24, 2017 | $137.60M | Aug 23, 2019 |
| FY2018 | Jun 25, 2016 | $161.70M | Aug 24, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 28, 2025 | $142.00M | Aug 21, 2025 |
| FY2025 | Jun 29, 2024 | $135.90M | Aug 21, 2025 |
| FY2025 | Jun 24, 2023 | $331.50M | Aug 21, 2025 |
| FY2024 | Jun 25, 2022 | $462.70M | Aug 23, 2024 |
| FY2023 | Jun 26, 2021 | $319.20M | Aug 18, 2023 |
| FY2022 | Jun 27, 2020 | $221.80M | Aug 22, 2022 |
| FY2021 | Jun 29, 2019 | $154.20M | Aug 23, 2021 |
| FY2020 | Jun 30, 2018 | $145.00M | Aug 21, 2020 |
| FY2019 | Jun 24, 2017 | $152.90M | Aug 23, 2019 |
| FY2018 | Jun 25, 2016 | $256.60M | Aug 24, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 28, 2025 | $25.80M | Aug 21, 2025 |
| FY2025 | Jun 29, 2024 | $33.80M | Aug 21, 2025 |
| FY2025 | Jun 24, 2023 | $34.20M | Aug 21, 2025 |
| FY2024 | Jun 25, 2022 | $31.10M | Aug 23, 2024 |
| FY2023 | Jun 26, 2021 | $21.10M | Aug 18, 2023 |
| FY2022 | Jun 27, 2020 | $16.30M | Aug 22, 2022 |
| FY2021 | Jun 29, 2019 | $23.70M | Aug 23, 2021 |
| FY2020 | Jun 30, 2018 | $34.10M | Aug 21, 2020 |
| FY2019 | Jun 24, 2017 | $31.40M | Aug 23, 2019 |
| FY2018 | Jun 25, 2016 | $28.60M | Aug 24, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 28, 2025 | $2.58B | Aug 21, 2025 |
| FY2025 | Jun 29, 2024 | $2.83B | Aug 21, 2025 |
| FY2024 | Jun 24, 2023 | $2.61B | Aug 23, 2024 |
| FY2023 | Jun 25, 2022 | $2.86B | Aug 18, 2023 |
| FY2022 | Jun 26, 2021 | $2.23B | Aug 22, 2022 |
| FY2021 | Jun 27, 2020 | $1.69B | Aug 23, 2021 |
| FY2020 | Jun 29, 2019 | $1.41B | Aug 21, 2020 |
| FY2019 | Jun 30, 2018 | $1.50B | Aug 23, 2019 |
| FY2018 | Jun 24, 2017 | $1.27B | Aug 24, 2018 |
| FY2017 | Jun 25, 2016 | $1.30B | Aug 18, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 28, 2025 | $1.19B | Aug 21, 2025 |
| FY2025 | Jun 29, 2024 | $1.36B | Aug 21, 2025 |
| FY2024 | Jun 24, 2023 | $1.37B | Aug 23, 2024 |
| FY2023 | Jun 25, 2022 | $1.59B | Aug 18, 2023 |
| FY2022 | Jun 26, 2021 | $1.26B | Aug 22, 2022 |
| FY2021 | Jun 27, 2020 | $874.70M | Aug 23, 2021 |
| FY2020 | Jun 29, 2019 | $752.50M | Aug 21, 2020 |
| FY2019 | Jun 30, 2018 | $770.50M | Aug 23, 2019 |
| FY2018 | Jun 24, 2017 | $526.50M | Aug 24, 2018 |
| FY2017 | Jun 25, 2016 | $595.20M | Aug 18, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 28, 2025 | $1.39B | Aug 21, 2025 |
| FY2025 | Jun 29, 2024 | $1.47B | Aug 21, 2025 |
| FY2025 | Jun 24, 2023 | $1.24B | Aug 21, 2025 |
| FY2025 | Jun 25, 2022 | $1.27B | Aug 21, 2025 |
| FY2024 | Jun 26, 2021 | $967.20M | Aug 23, 2024 |
| FY2023 | Jun 27, 2020 | $819.10M | Aug 18, 2023 |
| FY2022 | Jun 29, 2019 | $656.40M | Aug 22, 2022 |
| FY2021 | Jun 30, 2018 | $729.30M | Aug 23, 2021 |
| FY2020 | Jun 24, 2017 | $740.20M | Aug 21, 2020 |
| FY2019 | Jun 25, 2016 | $705.00M | Aug 23, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 28, 2025 | $872.30M | Aug 21, 2025 |
| FY2025 | Jun 29, 2024 | $816.40M | Aug 21, 2025 |
| FY2024 | Jun 25, 2023 | $816.40M | Aug 23, 2024 |
| FY2025 | Jun 24, 2023 | $816.40M | Aug 21, 2025 |
| FY2024 | Jun 25, 2022 | $806.60M | Aug 23, 2024 |
| FY2023 | Jun 26, 2021 | $570.00M | Aug 18, 2023 |
| FY2022 | Jun 27, 2020 | $360.80M | Aug 22, 2022 |
| FY2021 | Jun 29, 2019 | $372.80M | Aug 23, 2021 |
| FY2020 | Jun 30, 2018 | $372.80M | Aug 21, 2020 |
| FY2019 | Jun 24, 2017 | $206.80M | Aug 23, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 28, 2025 | $1.19B | Aug 21, 2025 |
| FY2025 | Jun 29, 2024 | $1.24B | Aug 21, 2025 |
| FY2024 | Jun 24, 2023 | $1.11B | Aug 23, 2024 |
| FY2023 | Jun 25, 2022 | $1.04B | Aug 18, 2023 |
| FY2022 | Jun 26, 2021 | $781.00M | Aug 22, 2022 |
| FY2021 | Jun 27, 2020 | $701.40M | Aug 23, 2021 |
| FY2020 | Jun 29, 2019 | $583.50M | Aug 21, 2020 |
| FY2019 | Jun 30, 2018 | $606.40M | Aug 23, 2019 |
| FY2018 | Jun 24, 2017 | $714.10M | Aug 24, 2018 |
| FY2017 | Jun 25, 2016 | $665.30M | Aug 18, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 28, 2025 | $391.50M | Aug 21, 2025 |
| FY2025 | Jun 29, 2024 | $876.90M | Aug 21, 2025 |
| FY2024 | Jun 24, 2023 | $924.70M | Aug 23, 2024 |
| FY2023 | Jun 25, 2022 | $824.00M | Aug 18, 2023 |
| FY2022 | Jun 26, 2021 | $836.30M | Aug 22, 2022 |
| FY2021 | Jun 27, 2020 | $763.40M | Aug 23, 2021 |
| FY2020 | Jun 29, 2019 | $327.80M | Aug 21, 2020 |
| FY2019 | Jun 30, 2018 | $301.00M | Aug 23, 2019 |
| FY2019 | Jun 24, 2017 | $367.80M | Aug 23, 2019 |
| FY2019 | Jun 25, 2016 | $352.20M | Aug 23, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 28, 2025 | $834.80M | Aug 21, 2025 |
| FY2025 | Jun 29, 2024 | $972.90M | Aug 21, 2025 |
| FY2024 | Jun 24, 2023 | $991.00M | Aug 23, 2024 |
| FY2023 | Jun 25, 2022 | $997.00M | Aug 18, 2023 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 28, 2025 | (1) | Aug 21, 2025 |
| FY2025 | Jun 29, 2024 | 3 | Aug 21, 2025 |
| FY2025 | Jun 24, 2023 | 1 | Aug 21, 2025 |
| FY2024 | Jun 25, 2022 | 6 | Aug 23, 2024 |
| FY2023 | Jun 26, 2021 | 2 | Aug 18, 2023 |
| FY2022 | Jun 27, 2020 | 3 | Aug 22, 2022 |
| FY2021 | Jun 29, 2019 | 0 | Aug 23, 2021 |
| FY2020 | Jun 30, 2018 | (3) | Aug 21, 2020 |
| FY2019 | Jun 24, 2017 | 1 | Aug 23, 2019 |
| FY2018 | Jun 25, 2016 | 1 | Aug 24, 2018 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 28, 2025 | (1) | Aug 21, 2025 |
| FY2025 | Jun 29, 2024 | 3 | Aug 21, 2025 |
| FY2025 | Jun 24, 2023 | 1 | Aug 21, 2025 |
| FY2024 | Jun 25, 2022 | 6 | Aug 23, 2024 |
| FY2023 | Jun 26, 2021 | 2 | Aug 18, 2023 |
| FY2022 | Jun 27, 2020 | 3 | Aug 22, 2022 |
| FY2021 | Jun 29, 2019 | 0 | Aug 23, 2021 |
| FY2020 | Jun 30, 2018 | (3) | Aug 21, 2020 |
| FY2019 | Jun 24, 2017 | 1 | Aug 23, 2019 |
| FY2018 | Jun 25, 2016 | 1 | Aug 24, 2018 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 28, 2025 | 38.64M | Aug 21, 2025 |
| FY2025 | Jun 29, 2024 | 39.57M | Aug 21, 2025 |
| FY2024 | Jun 24, 2023 | 38.57M | Aug 23, 2024 |
| FY2023 | Jun 25, 2022 | 39.62M | Aug 18, 2023 |
| FY2022 | Jun 26, 2021 | 35.33M | Aug 22, 2022 |
| FY2021 | Jun 27, 2020 | 34.12M | Aug 23, 2021 |
| FY2020 | Jun 29, 2019 | 33.35M | Aug 21, 2020 |
| FY2019 | Jun 30, 2018 | 35.25M | Aug 23, 2019 |
| FY2018 | Jun 24, 2017 | 34.64M | Aug 24, 2018 |
| FY2017 | Jun 25, 2016 | 35.21M | Aug 18, 2017 |